Elena K. Schneider1,2,*

1Department of Pharmacology & Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC 3010, Australia; 2Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences; Monash University, Parkville, VIC 3052, Australia

Abstract: Background & Objective: Since the release of ivacaftor-lumacaftor, several red-flags have been raised that highlight the clinical efficacy of this combination strategy that may be limited due to antagonistic drug-drug interactions.

Method: The effect of ivacaftor, its major metabolites M1 and M6, lumacaftor and the novel cystic fibrosis transmembrane conductance regulator (CFTR) modulator tezacaftor at 10 μg/mL on the enzymatic activity of the major xenobiotic metabolizing enzymes CYP1A2 and CYP3A4 as well as the minor enzymes CYP2B6 and CYP2C9 was assayed.

Results: Lumacaftor (3.74 x 10^5 ± 3.11 x 10^4 RLU), and ivacaftor-M6 (3.43 x 10^5 ± 7.61 x 10^4 RLU) markedly induced the activity of CYP3A4. Ivacaftor (2.22 x 10^5 ± 3.94 x 10^4 RLU) showed a lower relative ratio of luminescence units compared to chloramphenicol (3.17 x 10^5 ± 1.55 x 10^4 RLU). Interestingly, ivacaftor-M1 (6.74 x 10^4 ± 3.09 x 10^4 RLU) and the novel CFTR modulator tezacaftor (2.40 x 10^4 ± 8.14 x 10^3 RLU) did not show CYP3A4 induction. In the CYP1A2 and CYP2C9 assay, all metabolites showed a decrease in the ratio of luminescence units compared to the controls. Ivacaftor, its major metabolites, lumacaftor and tezacaftor all showed a slight increase in the ratio of luminescence units compared to the control rifampin with CYP2B6.

Conclusion: In all, present findings would suggest that lumacaftor and ivacaftor-M6 are strong inducers of CYP3A4, potentially reducing ivacaftor concentrations; ivacaftor itself induces CYP3A4 to some extent.

Keywords: Cystic fibrosis, ivacaftor, lumacaftor, CFTR modulator, cytochrome, drug interactions.

1. INTRODUCTION

Cystic Fibrosis (CF) is an autosomal recessive genetic life limiting disease that is caused by defective or deficient cystic fibrosis Transmembrane Conductance Regulator (CFTR) protein [1]. Ivacaftor (Kalydeco) is the first FDA-approved CFTR modulator drug, with evidenced clinical efficacy producing a significant improvement in the lung function over placebo in CF patients bearing the G551D-CFTR missense mutation which is found in 4-5% of the CF population [2, 3]. Unfortunately, ivacaftor is not effective in CFTR missense mutation which is found in 4-5% of the CF population. Vertex gained approval for ivacaftor-lumacaftor (Orkambi), which combines ivacaftor with the CFTR corrector drug lumacaftor and has recently gained FDA approval of their new CFTR corrector tezacaftor. The clever strategy of combining a CFTR corrector which rescues F508del-CFTR to the cell surface with a modulator which potentiates CFTR channel activity, effectively expands the treatment window to the majority of the CF population [4]. Since the release of ivacaftor-lumacaftor combination, several red-flags have been raised that highlight the clinical efficacy of this clever combination strategy maybe be limited due to antagonistic drug-drug interactions (i.e. a case of lumacaftor versus ivacaftor) [5]. Firstly, unlike the experience with ivacaftor monotherapy, patients receiving ivacaftor-lumacaftor combination therapy displayed only modest improvements in lung function and pulmonary exacerbations [6]. Secondly, evidence has emerged from a number of independent laboratories that suggests that prolonged exposure to ivacaftor counteracts the corrector function of lumacaftor, by destabilizing the lumacaftor rescued mature glycoform of F508del-CFTR and reducing its surface expression [7, 8]. Such inhibitory interactions are especially
concerning given that lumacaftor only partially restores (11-15%) F508del CFTR surface expression [7, 8]. Thirdly, ivacaftor and lumacaftor are both very hydrophobic drugs and as such are ~99% bound to plasma proteins; which significantly limits the free (active) drug concentration [9, 10]. Lastly, clinical reports hint that lumacaftor may be an inducer of cytochrome (CYP) P450 drug metabolizing enzymes and paradoxically ivacaftor is a substrate of CYP3A4 [11-13]. Moreover, the product information sheet for ivacaftor-lumacaftor strongly contraindicates co-administration of strong CYP3A4 inducers such as rifampin or St. John’s Wort [11, 12]. Together, this would suggest potential antagonistic drug-drug interactions between lumacaftor and ivacaftor is at play where the former induces the metabolism of the latter. Overall, these factors maybe compounding together to limit the clinical efficacy of ivacaftor-lumacaftor therapy.

To investigate the impact of inter-individual variability of the ivacaftor monotherapy of ivacaftor-lumacaftor treatment due to cytochrome P4503A4 metabolism [6, 11, 14, 15], we have measured the plasma concentrations of ivacaftor and its active metabolite M1 (hydroxymethylivacaftor) and M6 (ivacaftorcarboxylate) and lumacaftor in human plasma in two compliant female patients: patient one treated with 150mg/q12h ivacaftor and patient two treated with 200mg/q12h lumacaftor/125mg/q12h ivacaftor (patient samples were previously used to validate the LC-MS assay to FDA standards [16]). Both patients did not receive any CYP3A4 inducers. Plasma samples were collected at steady state after >2 weeks of treatment and 2.5 h after dosing. Sputum samples were ~2-3 mL and collected over 2-3 h, post-dosing. Drug concentrations in patient plasma and sputum samples were determined by LC-MS (Table 1) [16, 17].

Our findings confirm that there was no impact of combination therapy on the M6 concentration in patient 2 (0.15 µg/mL which is comparable to the concentration in patient 1 (0.16 µg/mL) who received ivacaftor monotherapy. However, a major decrease in ivacaftor plasma concentrations was detected: 0.97 µg/mL in patient 1 compared to the levels 0.06 µg/mL in patient 2. Similarly, a decreased level of the active M1 metabolite was detected in patient 2 0.07 µg/mL, compared to patient 1 0.50 µg/mL. Surprisingly high lumacaftor plasma concentrations of 3.69 µg/mL were detected in patient 2. It seems contradictory that the ivacaftor concentration has been reduced from 150mg/q12h per se to 125mg/q12h when given with the CYP inducer lumacaftor. As lumacaftor improves the trafficking of the CFTR and not the gating activity, lumacaftor alone does not provide enough improvement for clinical benefit, the question presents itself whether the plasma concentration of ivacaftor in the ivacaftor-lumacaftor patient is clinically efficicious (Table 1)?

The effect of ivacaftor, its major metabolites M1 and M6, lumacaftor and the novel CFTR modulator tezacaftor at 10 µg/mL on the enzymatic activity of the major xenobiotic metabolizing enzymes CYP1A2 and CYP3A4 as well as the minor enzymes CYP2B6 and CYP2C9 was assayed (Fig. 1). Measurement of the cytochrome activity in vitro was determined using the P450-Glo luminescence assay (Promega) according to the manufacturer’s instructions. Human recombinant enzymes were purchased from Sigma-Aldrich. In brief, for the P450-Glo assays, a 50 µL reaction mixture containing CYP enzyme 400 mM KPO4 buffer and a lumogenic CYP-specific substrate, were mixed with an equal volume of test compound and the mixture was incubated at room temperature for 10 min. Following incubation, an equal volume of NADPH regenerating system solution (2.6 mM NADP+, 6.6 mM glucose-6-phosphate, 6.6 mM MgCl2 and 0.8 U/mL glucose-6-phosphate dehydrogenase) was added. The reaction mixture was incubated at room temperature for 30 min. Luciferin detection reagent was then added and the mixture was incubated at room temperature for 20 min. The luminescence was then measured using a micro plate luminescence PerkinElmer EnSight Plate Reader. Lumacaftor

Table 1. Drug and metabolite concentrations in plasma and sputum in CF patients receiving Kalydeco and Orkambi therapy.

| Medication Management |
|-----------------------|
| Patient 1              |
| 150mg/q12h ivacaftor, 750 mg ciprofloxacine bd¹, inhaled tobramycin 112mg/bd 250/25µg bd seretide, mometasone nasal spray 2 sprays/bd, 100 µg salbutamol 2 puffs bd plus pm¹, pancreatic extract tds with meals, 500mg/d Calcium/400IU/d Vitamin D bd, 600mg salt pm |
| Patient 2              |
| 200mg/q12h lumacaftor and 125mg/q12h ivacaflor Pancreatic extract, 25 µg/d vitamin D, 20mg/d pantoprazole, 100mg/d nizatidine, 500mg/m/w/f azithromycin, hypertonic saline 6%, 5mL bd, 250/25 mg/d salmeterol, 2x/d Vitamin ABDECK, 2 salt tablets, 2mg/35mcg /d ethinyleoestradiol/cyproterone acetate, 100mcg/prn salbutamol, inhaled tobramycin |

| Plasma concentrations ** |
|--------------------------|
| KALYDECO Patient 1       |
| Plasma css               |
| 0.73±0.02                |
| IVA [µg/mL]              |
| IVA M1 [µg/mL]           |
| IVA M6 [µg/mL]           |
| LUMA [µg/mL]             |
| Plasma 2.5h              |
| 0.97±0.31                |
| 0.50±0.09                |
| 0.16±0.04                |
| ORKAMBI Patient 2        |
| Plasma 2.5 h             |
| 0.06±0.01                |
| 0.07±0.01                |
| 0.15±0.03                |
| 4.42±0.67                |

¹Every 12 hours; ² twice daily; ³ as needed; ⁴ 3 times per day; *below the limit of quantification (LOQ)

** Plasma concentrations were first reported by Schneider et al (2016) [16].
Comparison to the control rifampin (4.52 x 10² ± 8.06 x 10¹ RLU), its major metabolites, lumacaftor and tezacaftor all showed slight induction of CYP3A4 (Fig. I). Iva-cafort (2.22 x 10⁵ ± 3.94 x 10⁴ RLU) showed a lower relative ratio of luminescence units compared to chloramphenicol (3.17 x 10⁵ ± 1.55 x 10⁴ RLU). Interestingly, ivacaftor-M1 (6.74 x 10⁴ ± 3.09 x 10⁴ RLU) and the novel CFTR modulator tezacaftor (2.40 x 10⁴ ± 8.14 x 10³ RLU) did not show CYP3A4 induction. In the CYP1A2 and CYP2C9 assay, all metabolites showed a decrease in the ratio of luminescence units compared to the controls omeprazole (1.88 x 10⁴ ± 5.19 x 10³ RLU), and rifampicin (1.18 x 10⁴ ± 2.46 x 10³ RLU), respectively. Iva-caftor, its major metabolites, lumacaftor and tezacaftor all showed slight increase in the ratio of luminescence units compared to the control rifampin (4.52 x 10⁴ ± 8.06 x 10¹ RLU) with CYP2B6.

We have previously reported that co-medication with other CF drugs could impact the free plasma levels of ivacaftor, either via displacement from plasma binding proteins or induction or inhibition of cytochrome P450 metabolism [10]. Ciprofloxacin and other quinolone antibiotics have been reported to be potent CYP1A2 inhibitors [18]. Some evidence was reported that ciprofloxacin inhibits CYP3A4, albeit at the extraordinarily high concentration of 2 mM, which is not remotely achievable in patients (C_max = 2.34 ± 1.15 µg/mL) [19, 20]. Although, patient 1 was taking ciprofloxacin (750 mg/bd), given the very weak inhibitory activity of ciprofloxacin against CYP3A4, this co-medication is unlikely to be the cause of the higher ivacaftor plasma concentrations observed in this patient’s plasma.

All in all, present findings would suggest that lumacaftor and ivacaftor-M6 are strong inducers of CYP3A4, potentially reducing ivacaftor concentrations; ivacaftor itself induces CYP3A4 to some extent. Promisingly, the new CFTR modulator tezacaftor and also ivacaftor-M1 did not show CYP3A4 induction. Iva-caftor, its major metabolites, lumacaftor and tezacaftor all showed slight induction of CYP2B6 and no induction of CYP1A2 or CYP2C9. As lumacaftor therapy alone did not result in significant patient outcomes, the question remains if the concentrations of ivacaftor in ivacaftor-lumacaftor therapy are above the therapeutic threshold and if therapeutic drug monitoring protocols should be put in place [21]. This strategy would lead to better patient outcomes and greatly benefit patients.

**ETHICS APPROVAL AND CONSENT TO PARTICI-PATE**

Not applicable.

**HUMAN AND ANIMAL RIGHTS**

No Animals/Humans were used for studies that are base of this research.
CONSENT FOR PUBLICATION

Not applicable.

CONFLICT OF INTEREST

The author declares no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Bobadilla, J.L.; Macek, M.Jr.; Fine, J.P.; Farrell, P.M. Cystic fibrosis: A worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum. Mutat., 2002, 19(6), 75-606.

[2] Ramsey, B.W.; Davies, J.; McElvaney, N.G.; Tullis, E.; Bell, S.C.; Drevinek, M.; Griese, M.; Konstan, M.W.; Moss, R.; Ratjen, F.; Sermet-Gaudelus, I.; Rowe, S.M.; Dong, Q.; Rodriguez, S.; Yen, K.; Ordonez, C.; Elborn, J.S.A. CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med., 2011, 365(18), 1663-1672.

[3] Schneider, E.K.; Reyes-Ortega, F.; Li, J.; Velkov, T. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor? Clin. Pharmacol. Ther., 2017, 101(1), 130-141.

[4] Wainwright, C.E.; Elborn, J.S.; Ramsey, B.W.; Marigowda, G.; Huang, X.; Cipolli, M.; Comoiso, C.; Davies, J.C.; De Boeck, K.; Flume, P.A.; Konstan, M.W.; McColley, S.A.; McCoy, K.; McKone, E.F.; Munck, A.; Ratjen, F.; Rowe, S.M.; Walz, D.; and Boyle, M.P. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N. Engl. J. Med., 2015, 373(3), 220-231.

[5] Cholon, D.M.; Esther, C.R.; Gentzsch, M. Efficacy of lumacaftor-ivacaftor for the treatment of Cystic Fibrosis patients homozygous for the F508del-CFTR mutation. Expert Rev. Preci. Med. Drug Devel., 2016, 13(3), 235-243.

[6] FDA, Sponsor Briefing Document: ORKAMBI (Lumacaftor/Ivacaftor) for the Treatment of Cystic Fibrosis in Patients Age 12 Years and Older Who Are Homozygous for the F508del Mutation in the CFTR Gene. F.A.C.B.M.V.-F.P.-A.d.a. committe, Editor. 2015, VERTEX Pharmaceuticals Incorporated. p. 98.

[7] Cholon, D.M.; Quinney, N.L.; Fulcher, M.L.; Esther, C.R.Jr.; Das, J.; Dokholyan, N.V.; Randell, S.H.; Boucher, R.C.; Gentzsch, M. Potentiator ivacaftor abbreviates pharmacological correction of DeltaF508 CFTR in cystic fibrosis. Sci. Transl. Med., 2014, 6(246), 246-296.

[8] Veit, G.; Avramesca, R.G.; Perdomo, D.; Phuan, P.W.; Bagdany, M.; Apaja, P.M.; Borot, F.; Szollosi, D.; Wu, Y.S.; Finkbeiner, W.E.; Hegedus, T.; Verkman, A.S.; Lukacs, G.L. Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression. Sci. Transl. Med., 2014, 6(246), 246-297.

[9] Matthes, E.; Goeppe, J.; Carlile, G.W.; Luo, Y.; Dejaard, K.; Billet, A.; Robert, R.; Thomas, D.Y.; and Hanrahan, J.W. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor). Br. J. Pharmacol., 2016, 173(3), 459-470.

[10] Schneider, E.K.; Huang, J.X.; Carbone, V.; Baker, M.; Azad, M.A., Cooper, M.A.; Li, J.; Velkov, T. Drug-drug plasma protein binding interactions of ivacaftor. J. Mol. Recognit., 2015, 28(6), 339-348.

[11] VERTEX, Highlights of prescribing information ORKAMBI tablets for oral use. 2015, Vertex prescribing information.

[12] EMA, Assessment report ORKAMBI (ivacaftor/lumacaftor) European medicines agency EMEA/H/C/003954/0000, in European medicines agency EMEA/H/C/003954/0000. 2015.

[13] Taylor-Cousar, J.L.; Munck, A.; McKone, E.F.; van der Ent, C.K.; Moeller, A.; Simard, C.; Wang, L-T.; Ingenito, E.P.; McKee, C.; Lu, Y.; Lekstrom-Himes, J.; Elborn, J.S. Tezacafor-Ivacaftor in patients with Cystic Fibrosis homozygous for Phe508del. N. Engl. J. Med., 2017, 377(21), 2013-2023.

[14] EMA, Assessment report KALYDECO ivacaftor European Medicines Agency EMA/473279/2012 in European Medicines Agency EMA/473279/2012.

[15] Satomi, Y.; Nishino, H. Inhibition of the enzyme activity of cytochrome P450 1A1, 1A2 and 3A4 by furoxanthin, a marine carotenoid. Oncol. Lett., 2013, 6(3),860-864.

[16] Schneider, E.K.; Reyes-Ortega, F.; Wilson, J.W.; Kotsimbos, T.; Keating, D.; Li, J.; Velkov, T. Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO. J. Chromatogr. B. Ana.-lyt. Technol. Biomed. Life Sci., 2016, 1038, 57-62.

[17] Schneider, E.K.; Reyes-Ortega, F.; Li, J.; Velkov, T. Optimized LC-MS/MS method for the high-throughput analysis of clinical samples of Ivacaftor, its major metabolites, and lumacaftor in biological fluids of Cystic Fibrosis patients. J. Vis. Exp., 2017 (128).

[18] Fuhr, U.; Anders, E.M.; Mahr, G.; Sorgel, F.; Staib, A.H. Inhibitory potency of quinolone bacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob. Agents Chemother., 1992, 36(5),942-948.

[19] McLellan, R.A.; Drobitch, R.K.; Monshouwer, M.; Renton, K.W. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab. Dispos., 1996, 24, 1134-1138.

[20] Szalek, E.; Kaminska, A.; Godzik-Spychalska, J.; Grzeskowiak, E.; Batura-Gabryel, H. The PK/PD index (CMAX/MIC) for ciprofloxacin in patients with cystic fibrosis. Acta. Pol. Pharmac., 2011, 60(5), 777-783.

[21] Lynch, T.; Price, A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am. Fam. Physician, 2007, 76(3), 391-396.